Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Pecavaptan in Renal Impairment
NCT05599997Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pecavaptan in congestive heart failure (CHF) (4 arms), sponsored by Bayer. Primary endpoints: Area under the concentration versus time curve from zero to infinity divided by dose of total Pecavaptan, Maximum observed drug concentration divided by dose of total Pecavaptan and 2 more. Started Nov 2019; status: completed.
02
Drugs
pecavaptan
03
Conditions
congestive heart failure (CHF)
Beyond the preview
Go deeper on NCT05599997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599997.